NA

Nucleic Acid Therapeutics

Nucleic Acid Therapeutics focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The journal examines new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for clinical purposes.

Looking to publish in Nucleic Acid Therapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Existing customer login
Subject Medicine, Research & Experimental
Impact Factor 4.7
Quartile Q2
Open Access Type Hybrid
ISSN 2159-3337
eISSN 2159-3345
Invitation Only No
Cost Range Title-specific APCs apply under Sage Choice pricing; some society-owned titles may also charge page or publication fees in addition to the Sage Choice fee.

Submission Instructions

Nucleic Acid Therapeutics accepts the following article types. Click on an article type to view submission instructions.

Original Paper

Cover Letter Any third-party writing or editing assistance and any non-author who submits on behalf of the authors must be disclosed in the covering letter.
Abstract Original Paper submissions must include an unstructured abstract. The abstract must not exceed 200 words. The abstract must be unstructured.
Manuscript Original Paper submissions have a 4,000-word limit. The main manuscript should generally include Abstract, Introduction, Methodology, Results, Discussion, Conclusion, Acknowledgments, Statements and Declarations, and References. Include at least 4 keywords after the abstract, an Author Contributions section after the Acknowledgements, a Statements and Declarations section with all required declaration headings including 'Not applicable' where relevant, and disclose AI use in the Acknowledgements or Methodology section when required.
References References must follow Sage Vancouver style. References must be numbered in the order cited, use superscript numerals in the text after punctuation, abbreviate journal titles according to Index Medicus, and list up to three authors before using et al. for additional authors.
Figures & Tables Original Paper submissions may include a maximum total of five figures and/or tables. Figures, charts, and tables created in Word should be included in the main text, while figures and other files created outside Word should be submitted separately with a placeholder note in the text. Figures and tables must be numbered consecutively, figures and tables must include a number and title, tables must be editable text rather than images, and raw data for figures must be provided.
Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Review Articles

Cover Letter A cover letter is required when third-party writing or editing assistance was used or when someone not listed as an author submitted on behalf of the authors. The cover letter must disclose any third-party writing or editing assistance and any submission made on behalf of the authors by a non-author.
Abstract An abstract is required. The abstract must be unstructured and no more than 200 words. The abstract must be unstructured.
Manuscript The manuscript must not exceed 10,000 words, excluding the abstract, disclosure statements, author contribution statements, funding information, acknowledgments, tables, figure legends, and references. The main manuscript should generally include Abstract, Introduction, Methodology, Results, Discussion, Conclusion, Acknowledgments, Statements and Declarations, and References, with clear heading levels and clearly defined sections. Include at least 4 keywords after the abstract, an Author Contributions section after the Acknowledgements, a Statements and Declarations section with all required declaration headings including 'Not applicable' where relevant, and disclose AI use in the Acknowledgements or Methodology section when required.
References References must follow Sage Vancouver style. References must be numbered in the order cited, use abbreviated journal titles per Index Medicus, list up to three authors followed by et al. for additional authors, and use superscript numerals in the text after punctuation.
Figures & Tables Review Articles may include a maximum total of 10 figures and/or tables. Figures, charts, and tables created in Word should be included in the main text, while figures and other files created outside Word should be submitted separately with a placeholder note in the text. Tables must be editable text with a number and title, and all figures and tables must be numbered consecutively in the order they are cited.
Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Brief Communications

Cover Letter A cover letter is required only if third-party writing or editing assistance was used or if the submission was made by someone who is not an author. The cover letter must disclose any third-party writing or editing assistance and state if the submission was made on behalf of the authors by a non-author.
Abstract Brief Communications must include an abstract. The abstract must be unstructured and no more than 150 words. The abstract must be unstructured.
Manuscript The manuscript must not exceed 1,000 words, excluding the abstract, disclosure statements, author contribution statements, funding information, acknowledgments, tables, figure legends, and references. Brief Communications may combine the Results and Discussion sections. Include at least 4 keywords after the abstract, an Author Contributions section after the Acknowledgements, and a Statements and Declarations section with all required declaration subheadings, using 'Not applicable' where a declaration does not apply.
References References must follow Sage Vancouver style. References must be numbered in the order cited, use abbreviated journal titles per Index Medicus, list up to three authors before using et al., and text citations must be superscript numerals placed after punctuation.
Figures & Tables Brief Communications may include a maximum of three figures and/or tables. Figures, charts, and tables created in Word should be embedded in the main text, while figures created outside Word should be uploaded separately with a placeholder in the text. Tables must be editable text with a number and title, and all figures and tables must be numbered consecutively in the order cited.
Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Letters To The Editor

Cover Letter Any third-party writing or editing assistance and any submission made by a non-author on behalf of the authors must be stated in the covering letter.
Abstract Abstract must not exceed 200 words. Abstract must be unstructured.
Manuscript Letters to the Editor must not exceed 500 words. Include at least 4 keywords after the abstract, an Author Contributions section after the Acknowledgements, and a Statements and Declarations section with all required declaration headings, using “Not applicable” where a declaration does not apply.
References Letters to the Editor may include a maximum of four references. References must follow Sage Vancouver style. References must be numbered in the order cited, use Index Medicus journal title abbreviations, list up to three authors before using et al., and text citations must be superscript numerals placed after punctuation.
Figures & Tables Letters to the Editor may include one figure or one table. Figures, charts, and tables created in Word should be included in the main text, while figures created outside Word should be submitted separately with a placeholder note in the text. Tables must be editable text with a number and title, and figures must be numbered consecutively and include a number and title.
Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Recent Publications

Antisense Oligonucleotides that Are Toxic to Prion-Infected Mice Share an Emergent Mechanism

Hien T. Zhao, Jill O’Moore, Daniel A. Sprague, Juliana E. Gentile, Sagar Damle, Briana Noble, Taylor L. Corridon, Simone Lord, Jason Le, Samantha Graffam, Michael Howard, Kendrick DeSouza-Lenz, Hongda Li, John Matson, Susan Li, Stephanie Klein, Tyler Caron, Alissa A. Coffey, Sonia M. Vallabh, Holly B. Kordasiewicz, Andrea Grindeland Panter, Eric Vallabh Minikel

10.1177/21593337261494829
View Publication

Nonclinical Development of Oligonucleotide-Based Therapeutics: Insights from an IQ DruSafe ONT Working Group Survey

Tod A. Harper Jr, Yi Yang, Sucheta Mukherjee, Marie Coeffet, Katja A. Matheis, Alan Brown, Joel D. Parry, Patrik Andersson, Onyi N. Irrechukwu, Michaël Maes, Marc F. DeCristofaro, Daniella M. Pizzurro, Meredith Crosby, Jennifer D. Sisler

10.1177/21593337261494828
View Publication

Incorporation of a pH-Sensitive Linker into Lipid–ASO Conjugates Drives Increased Endosomal Membrane Remodeling Events

Priyanka Mangla, Emma Kay, Michael J. Munson, Daniel van Leeuwen, Kathrin Stavenhagen, Smita Nahar, Annabelle Biscans

10.1177/21593337261488803
View Publication

rHuPH20 Enhances Extravascular Delivery of mRNA Lipid Nanoparticles in Mice and Minipigs

Ryan P. Nolan, Marie A. Printz, David W. Kang, Robert J. Connor, Yan Wang, Limin Liu, Chris Wahl

10.1177/21593337261479163
View Publication

Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits

Katarina D. Kovacevic Miljević, Shuhao Zhu, James C. Gilbert, Warren Harvey, Paul Tarantino, Bernd Jilma

10.1177/21593337261476421
View Publication

Frequently asked questions

How long does it take to publish?

Peer review averages 25 days from submission to first decision, and online publication occurs within four weeks of acceptance.

Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Is a cover letter required?

A covering letter is required when third-party writing or editing assistance is received or when a submission is made on behalf of the authors by someone not listed as an author.

Reformat to Nucleic Acid Therapeutics using Livewrite Premium

What are the publication costs?

Title-specific APCs apply for Sage Choice hybrid open access after acceptance; some society-owned titles may also charge page or publication fees in addition to the APC.

Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Research Topics

RNA Interference and Gene Delivery Advanced biosensing and bioanalysis techniques DNA and Nucleic Acid Chemistry RNA and protein synthesis mechanisms CRISPR and Genetic Engineering RNA Research and Splicing MicroRNA in disease regulation Virus-based gene therapy research Muscle Physiology and Disorders RNA modifications and cancer Neurogenetic and Muscular Disorders Research Immune Response and Inflammation RNA regulation and disease Immunotherapy and Immune Responses interferon and immune responses Genetic Neurodegenerative Diseases Bacteriophages and microbial interactions Monoclonal and Polyclonal Antibodies Research Viral Infections and Immunology Research Molecular Biology Techniques and Applications Immune Cell Function and Interaction Cancer-related molecular mechanisms research Blood Coagulation and Thrombosis Mechanisms Pluripotent Stem Cells Research Retinal Development and Disorders

Related Journals

JO
Journal of Cellular and Molecular Medicine WILEY
AP
AIDS Patient Care and STDs Mary Ann Liebert, Inc.
MB
Molecular Biomedicine Springer Nature
TK
The Kaohsiung Journal of Medical Sciences WILEY
PR
PPAR Research Hindawi Publishing Corporation
LH
LGBT Health Mary Ann Liebert, Inc.